28S Ribosomal Subunit as a Drug Target or Biomarker: A Promising Approach for the Treatment of Mitochondrial Disorders

Target Name: 28S ribosomal subunit, mitochondrial

NCBI ID: P25010

28S ribosomal subunit, mitochondrial

Other Name(s): None

28S Ribosomal Subunit as a Drug Target or Biomarker: A Promising Approach for the Treatment of Mitochondrial Disorders

Abstract:

Mitochondrial dysfunction is a common disorder affecting the energy metabolism of cells, leading to a range of symptoms, including muscle weakness, cognitive impairments, and progressive motor neuron diseases. The 28S ribosomal subunit (28S rRNA), a critical component of the mitochondrial ribosome, has been identified as a potential drug target or biomarker for the treatment of mitochondrial disorders. This article will discuss the current understanding of the 28S rRNA and its role in the development of mitochondrial dysfunction, as well as the potential benefits and challenges of targeting this protein for therapeutic intervention.

Introduction:

Mitochondria are organelles responsible for generating the majority of the energy for the cell through a process called cellular respiration. The mitochondria are also responsible for maintaining the integrity of the cell's DNA and for the production of the proteins and lipids that are essential for the cell's survival. Mitochondrial dysfunction, characterized by impaired cellular respiration and increased oxidative stress, is a common disorder that affects millions of people worldwide, including those with diseases such as Alzheimer's, Parkinson's, and Huntington's.

The 28S rRNA:

The 28S rRNA is a subunit of the mitochondrial ribosome, which is the protein complex responsible for producing the proteins and lipids that are synthesized by the mitochondria. The 28S rRNA is one of the four subunits of the ribosome, and its function is to bind to the 60S rRNA and form the active site for the initiation of protein synthesis.

The 28S rRNA has been identified as a potential drug target or biomarker for the treatment of mitochondrial disorders due to its unique structure and function. The 28S rRNA has a distinct N-terminal and C-terminal region, which contain unique variants of the protein that are involved in the initiation of protein synthesis and the formation of the active site for the ribosome. Additionally, the 28S rRNA has a distinct propensity to undergo structural changes, such as the formation of aggregates, which have been implicated in the development of certain mitochondrial diseases.

Targeting the 28S rRNA:

Several studies have suggested that targeting the 28S rRNA could be a promising approach for the treatment of mitochondrial disorders. One of the main advantages of targeting the 28S rRNA is its expression in most tissues, making it a potential target for small molecule inhibitors. Additionally, the 28S rRNA is involved in the production of a variety of proteins that are essential for the cell's survival, making it an attractive target for the development of protein-level inhibitors.

In addition to small molecule inhibitors, targeting the 28S rRNA with drugs that induce apoptosis (programmed cell death) could also be an effective approach for the treatment of mitochondrial disorders. Apoptosis is a natural response of cells to environmental stressors, and it is a mechanism that has been implicated in the development of many diseases, including neurodegenerative diseases. By inducing apoptosis, drugs can eliminate damaged cells and potentially slow the progression of disease.

The challenges and limitations of targeting the 28S rRNA:

While targeting the 28S rRNA as a drug target or biomarker for the treatment of mitochondrial disorders is a promising approach, there are several challenges and limitations that need to be addressed. One of the main challenges is the difficulty of targeting a protein with small molecules, which may limit the efficacy of inhibitors. Additionally, the 28S rRNA is involved in the production of a variety of proteins, which may make it difficult to

Protein Name: 28S Ribosomal Subunit, Mitochondrial

The "28S ribosomal subunit, mitochondrial Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about 28S ribosomal subunit, mitochondrial comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets